|Targets||PDGFR | VEGFR|
|Description||TSU-68 (SU6668; Orantinib) is a novel multiple receptor tyrosine kinase inhibitor with IC50 of 2.1 μM, 8 nM and 1.2 μM for VEGF-R1, PDGF-Rβ and FGF-R1, respectively; has greatest potency against PDGFR autophosphorylation.|
|Synonyms||TSU68; TSU 68; TSU-68; SU6668; SU 6668; SU-6668; NSC 702827; Orantinib.|
|Current Developer||Taiho Pharma Inc.|
SU 4312 is a potent and selective inhibitor of VEGFR and PDGFR tyrosine kinases (IC50 = 0.8 and 19.4 μM, respectively) wirth selectivity over EGFR and c-Src tyr...
Description of Linifanib: Linifanib is an orally bioavailable, small-molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. L...
AC710 is a potent, selective platelet-derived growth factor receptor-family kinase inhibitor with potential anticancer activity. AC710 is now a preclinical deve...
TG 100801 Hydrochloride
TG 100801 is the prodrug of TG 100572, which is a multi-targeted kinase inhibitor that inhibit select growth factor receptor tyrosine kinases and Src familt kin...
Potent and selective inhibitor of VEGFR2 (IC50: 2 nM for VEGFR2 vs >50 mM for VEGFR1 respectively)
KG 5 is a B-Raf allosteric and PDGFRβ inhibitor. It inhibits FLT3, KIT and c-Raf. It arrests cells in prometaphase and inhibits growth of renal and pancreatic t...
NVP-ACC789 is a potent, selective and orally active inhibitor of the VEGF receptor tyrosine kinases, antagonizing tumor-driven angiogenesis
JNJ 17029259 is an selective, nanomolar inhibitors of the vascular endothelial growth factor receptor-2 (VEGF-R2), blocks VEGF-stimulated mitogen-activated prot...